



Coming

soon

A Sysmex Group Company

Myeloid MRD Panel

Features

Designed in collaboration with leading cancer experts

 Detect SNVs and indels in 45 hotspot exons across 13 genes associated with accurate MRD detection in AML samples — including MDS and MPN implicated genes

Class-leading sensitivity

• Designed to detect low-frequency variants down to 0.05% VAF with confidence, even in challenging genes such as *NPM1*, *CEBPA* and *FLT3-ITD*

Rapid, cost-efficient and customisable

• Simultaneously assay multiple targets with a single, customisable NGS panel

Complimentary data analysis software

• Powerful and intuitive Interpret NGS Analysis Software for confident variant calling, including longitudinal monitoring

SureSeq

Myeloid MRD Panel

Introduction

Measurable residual disease (MRD) — the presence of cancerous cells below the threshold of detection of conventional morphologic methods — is routinely investigated post treatment to research the risk of relapse and to explore potential therapeutic strategies.

Several methodologies are currently used to assess MRD in acute myeloid leukaemia (AML), including immunophenotypic multiparameter flow cytometry (MFC), real-time quantitative polymerase chain reaction (RT-PCR), digital droplet PCR (ddPCR) and next-generation sequencing (NGS).

MFC provides valuable information about antigen expression implicated in MRD but does not assess genetic biomarkers, while PCR-based techniques are highly sensitive but are limited by the number of targets that can be detected simultaneously.

In contrast next-generation sequencing (NGS) offers highly sensitive and specific analysis of multiple AML-associated genes, allowing comprehensive MRD analysis of a wide-range of AML subtypes, including the identification of sample-specific mutations.

Expert-led, evidence-based content

The SureSeq[™] Myeloid MRD Panel has been designed in collaboration with leading cancer experts and in accordance with the European LeukemiaNet (ELN) recommendations¹ to offer a single, cost-effective NGS assay to investigate MRD in AML samples. The panel content incorporates key genes for assessing AML, including genes implicated in MPN and MDS to investigate secondary AML progression. In addition, genes related to research on potential drug response are included, for truly comprehensive and informative sample analysis.

Utilising OGT's intelligent panel design capabilities, the SureSeq Myeloid MRD Panel surpasses the typical sensitivities offered by alternative NGS panels to accurately detect SNVs, indels and internal tandem duplications (ITDs) down to 0.05% VAF.

Gene	Exons	Gene	Exons
CSF3R	Exons 13–17	FLT3	Exons 13–15 and 20
MPL	Exon 10	IDH2	Exons 4 and 5
SF3B1	Exons 13–16	TP53	Exons 2–11 (inc. NM_001276695:ex10, NM_001276696:ex10)
IDH1	Exon 4	CALR	Exon 9
KIT	Exons 2, 8–11, 13 and 17	RUNX1	Exons 4–8
NPM1	Exon 11	CEBPA	Exon 1
JAK2	Exons 12 and 14		

Table 1: The SureSeq Myeloid MRD Panel targets SNVs and indels in 45 hotspot exons across 13 genes associated with accurate MRD detection in AML samples, including MDS and MPN implicated genes to investigate AML progression. The assay also accurately detects *FLT3*-ITDs.

SureSeq

Myeloid MRD Panel

Unparalleled uniformity and depth of coverage

*NPM*1 is the most commonly mutated gene in adult AML, present in approximately 25–35% of cases², making it an essential marker for MRD monitoring. *NPM*1 mutations occur almost exclusively in exon 11; a difficult region to sequence due to multiple perfectly matched copies replicated across the genome. The sophisticated bait design used in the SureSeq Myeloid MRD Panel overcomes this issue to deliver exceptional coverage uniformity, enabling reliable detection of all target regions (Figure 1).





Figure 1: IGV plot showing high uniformity of coverage of all target regions in the panel, including NPM1 exon 11.

FLT3 internal tandem duplications (ITDs) are present in approximately 25% of AML cases and are an important negative prognostic marker³; however, their inherent repeat content and length (up to 300 bp⁴) make them challenging to target, and subsequently detect. As a result, they are masked in many gene panels, necessitating additional techniques to characterise these important mutations. The unique detection algorithms incorporated into the complimentary Interpret NGS Analysis Software enable accurate detection and quantification of *FLT3*-ITDs, including multiple and large ITDs (Figure 2).





Myeloid MRD Panel

Combining coverage uniformity with a focused, expert-led panel design allows greater sequencing depth, which further enhances sensitivity at lower sequencing cost. SNVs, indels and ITDs across all targeted genes and regions can be detected down to 0.05% VAF (Table 2).

	Gene Variant		Coordinate	0.1% VAF		0.05% VAF		Neg. ctrl	
		Variant		Read depth	Observed VAF	Read depth	Observed VAF	Read depth	Observed VAF
SNV	SF3B1	c.2219G>A	chr2:197401989	7426	0.13	14282	0.03	15076	0
	IDH1	c.394C>T	chr2:208248389	6743	0.09	15572	0.06	15734	0
	JAK2	c.1849G>T	chr9:5073770	10408	0.12	22348	0.08	22065	0
	FLT3	c.2503G>T	chr13:28018505	9747	0.11	24098	0.04	23942	0
	IDH2	c.515G>A	chr15:90088606	7294	0.08	16554	0.04	18875	0
	TP53	c.722C>T	chr17:7674241	5166	0.12	12609	0.03	13769	0
Indel	NPM1	c.860_863dup	chr5:171410539	8164	0.11	18630	0.07	17630	0
	JAK2	c.1611_1616del	chr9:5070021	12270	0.03	28197	0.02	25411	0
ITD	FLT3	ITD300	chr13:28033909	6045	≥ 0.1	12265	≥ 0.05	10473	0

Table 2: Detection of SNVs, indels and an ITD, with expected frequency ranges of 0.1%-0.05%. SNVs are filtered to remove unique molecular identifiers (UMI) with a read family size of one. The SureSeq Myeloid MRD Panel was used on a Myeloid Reference DNA Standard (Horizon Discovery) according to the standard protocol, with sequencing on a NextSeq[®] 500 (Illumina).

Rapid, streamlined workflow

All SureSeq NGS panels combine the superior performance of hybridisation-based enrichment with the streamlined and automatable Universal NGS Complete Workflow Solution to deliver unparalleled results with minimal hands-on time (Figure 3). The incorporation of Unique Molecular Identifiers (UMIs) and Unique Dual Indexes (UDIs) prior to sample amplification, allows true variants to be distinguished from PCR artefacts, for highly sensitive and reliable results.




Figure 3: The streamlined SureSeq Myeloid MRD Panel workflow.

SureSeq

Myeloid MRD Panel

Complimentary data analysis software

OGT's powerful and easy-to-use Interpret NGS Analysis Software facilitates analysis and visualisation of a wide range of somatic variants including structural aberrations. Designed to work seamlessly with

all SureSeg NGS panels, the software delivers fast and accurate detection of all SNVs, indels and ITDs. Following detection, all variants are displayed in the user-friendly variant browser, for effortless translation of all your myeloid MRD data into meaningful results. The reporting tool also enables visualisation of changing MRD dynamics over time (Figure 4). The software can be deployed locally or in the cloud to suit your analysis infrastructure.




Figure 4: Interpret NGS Analysis Software can load and display multiple data sets, enabling easy visualisation of genetic changes in longitudinal MRD sample studies.

Customisable, future-proof content

Science doesn't stand still, so we've made it easy for you to benefit from the latest scientific discoveries and guidance by customising the SureSeq Myeloid MRD Panel to meet your precise requirements. Choose from our regularly updated, expert-curated library of pre-optimised cancer content to create your ideal custom SureSeq myPanel[™] assay. Alternatively, browse our full range of myeloid panels, including the focused three-gene SureSeq Core MPN Panel and the SureSeq Pan-Myeloid Panel, incorporating key variants in 70 genes implicated in a wide range of myeloid disorders. In addition, the RNA-based SureSeq Myeloid Fusion Panel enables detection of 30 common fusions and novel fusion partners for key myeloid cancer genes.

SureSeq Myeloid MRD Panel: technical information

Feature	Specification				
Number of targets	45 hotspot exons from 13 genes				
Panel size	11.2 kb				
Mean target coverage	Up to 20,000x				
Limit of detection SNVs, indels, ITDs	0.05%	0.1%			
DNA input recommended	2 x 200 ng	200 ng			
Samples per run					
NextSeq 500 High Output	16	24			
NextSeq 2000 P3	48	72			
NovaSeq® SP	32	48			
NovaSeq S1	64	96			

Ordering information

UK +44 (0) 1865 856800 US +1 914 467 5285 contact@ogt.com ogt.com

	Coming soon)
Product	Contents	Cat. No.
SureSeq Myeloid MRD Complete NGS Workflow Solution V2 (48)	Enrichment baits sufficient for 12 hybridisation reactions. Bundle of 1 x Universal Library Preparation Kit (96) containing PCR primers and enzymes. 1 x Universal Hybridisation & Wash Kit V2 (96). 1 x Pre-PCR Universal Bead Kit (96). 1 x Post-PCR Universal Bead Kit (96). 1 x Universal Index Adapter Kit (96). Interpret NGS Analysis Software	780126-48
SureSeq Myeloid MRD Panel (48)	Enrichment baits sufficient for 12 hybridisation reactions. Interpret NGS Analysis Software	770026-48
Universal NGS Workflow Solution V2 (96)	Bundle of 1 x Universal Library Preparation Kit (96) containing PCR primers and enzymes, 1 x Universal Hybridisation & Wash Kit V2 (96). 1 x Pre-PCR Universal Bead Kit (96). 1 x Post-PCR Universal Bead Kit (96). 1 x Universal Index Adapter Kit (96)	770510-96

Request a quote at www.ogt.com or contact one of our experts at contact@ogt.com.

References

- 1. European LeukaemiaNET. Available at: www.leukemia-net.org.
- 2. Hindley et al., Int J Mol Sci 2021; 22(18):10040.
- 3. Daver et al., Leukemia 2019; 33: 299-312.
- 4. Spencer et al., J Mol Diagn 2013; 15(1):81-93.



A Sysmex Group Company

What binds us, makes us.

Oxford Gene Technology Ltd., Begbroke Science Park, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, UK

SureSeq: For Research Use Only: Not for Diagnostic Procedures. This document and its contents are © Oxford Gene Technology IP Limited – 2023. All rights reserved. OGT™ and SureSeq™ are trademarks of Oxford Gene Technology IP Limited. NextSeq and NovaSeq are trademarks of Illumina, Inc.

